Gastrointestinal Cancer

PT886 (Phanes Therapeutics) received fast track designation 2 years after receiving orphan drug designation by the FDA.

For more than 30 years, there has been little treatment advancement for NMIBC patients. Fortunately, a new development in the treatment of NMIBC has been approved by the FDA and is now available.

The approval of irinotecan liposome offers an improved first-line treatment option for individuals diagnosed with metastatic pancreatic adenocarcinoma.

This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.

Compared to TACE alone, durvalumab plus TACE and bevacizumab reduced the risk of disease progression or death by 23%; however, further research is needed to assess OS.

There was no statistically significant difference between Lovenox (Sanofi–Aventis Pharmaceuticals, France) and biosimilar enoxaparin in the occurrence of post-operative thrombosis for digestive cancer.

The approval makes pembrolizumab the first-line treatment for individuals with this cancer.

With this approval, fruquintinib is the first and only selective inhibitor of all 3 VEGR receptor kinases to be approved in the United States for previously treated mCRC, regardless of biomarker status.

Domvanalimab plus zimberelimab with chemotherapy demonstrated a positive overall response rate and 6-month progression free survival rate for patients with upper gastrointestinal cancers.

The approval marks the sixth indication for pembrolizumab in gastrointestinal cancers.

Mental health treatment may be necessary when SAEs occur.

The results also indicate an association with increased risk of colorectal and noncolorectal gastrointestinal cancers as body mass index increases over time.

Lutetium Lu177 dotatate demonstrated significant and clinically meaningful progression-free survival for those with SSTR-positive and inoperable midgut neuroendocrine tumor.

Overweight or obesity between middle and later adulthood had a statistically significant risk for noncolorectal gastrointestinal cancer.

Zolbetuximab treatment reduced risk of death by 25% compared to placebo.

In patients with HER2-expressing metastatic gastroesophageal adenocarcinoma administered zanidatamab, the median duration of response was 20.4 months, with a median progression-free survival of 12.5 months.

The analysis found a median progression-free survival of 14.2 months in the ripretinib arm, compared with 1.5 months in the sunitinib arm.

Like using good nutrients to grow tomatoes in the soil, good nutrients and diverse microbes are important for our good gut health, or our gut's "garden," said a leading researcher.

Findings in a new trial show that dietary supplementation of resistant starch has the potential to decrease people’s risk of certain types of gastrointestinal cancers.

In clinical trials, dabrafenib and trametinib showed meaningful efficacy in multiple BRAF-positive tumor types, including in patients with rare cancers who have no other treatment options available.

Any antibiotic use was associated with higher rates of IBD, and the risk went up substantially with each course.

Trastuzumab (Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant) is a HER2/neu receptor antagonist indicated for early and advanced breast cancer, advanced stomach cancer, and gastroesophageal junction cancer.

The research team suggests that healthy weight maintenance throughout adulthood is crucial in preventing colorectal adenoma.

Small GISTs may cause no symptoms and may grow so slowly that they have no serious effects.

The continued approval for this indication may be subject upon verification and description of clinical benefit in a confirmatory trial.

Nivolumab (Opdivo; Bristol Myers Squibb) is FDA approved for 11 cancer indications, with the most recent approval for use in combination with certain chemotherapy for the initial treatment of gastric cancer.

Primary results from the randomized portion of the INVICTUS study had previously shown that ripretinib was able to significantly improve progression-free survival with a clinically meaningful overall survival benefit in patients with advanced gastrointestinal stromal tumor.

Bemarituzumab is an investigational, potential first-in-class targeted antibody designed to block specific fibroblast growth factors from binding and activating FGFR2b.

Median disease-free survival was twice as long in patients who received nivolumab compared to patients who received a placebo.

Nivolumab is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival compared to chemotherapy alone in this patient population.